These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38518928)

  • 1. Fused thiophene as a privileged scaffold: A review on anti-Alzheimer's disease potentials via targeting cholinesterases, monoamine oxidases, glycogen synthase kinase-3, and Aβ aggregation.
    Kassab AE; Gedawy EM; Sayed AS
    Int J Biol Macromol; 2024 Apr; 265(Pt 2):131018. PubMed ID: 38518928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
    Mazumder MK; Choudhury S
    Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurobiology and therapeutic potential of multi-targeting β-secretase, glycogen synthase kinase 3β and acetylcholinesterase in Alzheimer's disease.
    Fronza MG; Alves D; Praticò D; Savegnago L
    Ageing Res Rev; 2023 Sep; 90():102033. PubMed ID: 37595640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in Target Drug Molecules for Alzheimer's Disease.
    Xie J; Liang R; Wang Y; Huang J; Cao X; Niu B
    Curr Top Med Chem; 2020; 20(1):4-36. PubMed ID: 31797761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Butyrylcholinesterase and Monoamine Oxidase B Targeted Ligands and their Putative Application in Alzheimer's Treatment: A Computational Strategy.
    Jabir NR; Rehman MT; Tabrez S; Alserihi RF; AlAjmi MF; Khan MS; Husain FM; Ahmed BA
    Curr Pharm Des; 2021; 27(20):2425-2434. PubMed ID: 33634754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.
    Barai P; Raval N; Acharya S; Borisa A; Bhatt H; Acharya N
    Behav Brain Res; 2019 Jan; 356():18-40. PubMed ID: 30118774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic implications of glycogen synthase kinase-3β in Alzheimer's disease: a novel therapeutic target.
    Mandlik DS; Mandlik SK; S A
    Int J Neurosci; 2024 Jun; 134(6):603-619. PubMed ID: 36178363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.
    Košak U; Strašek N; Knez D; Jukič M; Žakelj S; Zahirović A; Pišlar A; Brazzolotto X; Nachon F; Kos J; Gobec S
    Eur J Med Chem; 2020 Jul; 197():112282. PubMed ID: 32380361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenyl-quinoline derivatives as lead structure of cholinesterase inhibitors with potency to reduce the GSK-3β level targeting Alzheimer's disease.
    Noori M; Dastyafteh N; Safapoor S; Khalili Ghomi M; Tanideh R; Zomorodian K; Hamedifar H; Dara M; Zare S; Irajie C; Javanshir S; Rastegar H; Panahi N; Larijani B; Mahdavi M; Hajimiri MH; Iraji A
    Int J Biol Macromol; 2023 Dec; 253(Pt 7):127392. PubMed ID: 37827412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in the Development of Nitrogen-containing Heterocyclic Anti-alzheimer's Agents.
    Kumar A; Nehra B; Singh D; Kumar D; Chawla PA
    Curr Top Med Chem; 2023; 23(13):1277-1306. PubMed ID: 36278462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of amyloid-β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3β.
    Amin J; Paquet C; Baker A; Asuni AA; Love S; Holmes C; Hugon J; Nicoll JA; Boche D
    Neuropathol Appl Neurobiol; 2015 Jun; 41(4):445-57. PubMed ID: 25486988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology.
    Uddin MS; Kabir MT; Rahman MM; Mathew B; Shah MA; Ashraf GM
    J Pharm Pharmacol; 2020 Aug; 72(8):1001-1012. PubMed ID: 32149402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.
    León R; Garcia AG; Marco-Contelles J
    Med Res Rev; 2013 Jan; 33(1):139-89. PubMed ID: 21793014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic Insight into the Design of Chemical Tools to Control Multiple Pathogenic Features in Alzheimer's Disease.
    Han J; Du Z; Lim MH
    Acc Chem Res; 2021 Oct; 54(20):3930-3940. PubMed ID: 34606227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
    Liu W; Liu X; Liu W; Gao Y; Wu L; Huang Y; Chen H; Li D; Zhou L; Wang N; Xu Z; Jiang X; Zhao Q
    Eur J Med Chem; 2022 Feb; 229():114095. PubMed ID: 34995924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus.
    Hamodat H; Cash MK; Fisk JD; Darvesh S
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):571-583. PubMed ID: 28644906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic and urinary metabolomics studies on the mechanism of Schisandra polysaccharide in the treatment of Alzheimer's disease.
    Liu Y; Liu Z; Wei M; Hu M; Yue K; Bi R; Zhai S; Pi Z; Song F; Liu Z
    Food Funct; 2019 Jan; 10(1):432-447. PubMed ID: 30623955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway.
    Reale M; Di Nicola M; Velluto L; D'Angelo C; Costantini E; Lahiri DK; Kamal MA; Yu QS; Greig NH
    Curr Alzheimer Res; 2014; 11(6):608-22. PubMed ID: 24359497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
    Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F
    Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding Glycogen Synthase Kinase-3: A Novel Avenue for Alzheimer's Disease.
    Sequeira RC; Godad A
    Mol Neurobiol; 2024 Jul; 61(7):4203-4221. PubMed ID: 38064104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.